NCT06274593 Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
| NCT ID | NCT06274593 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-04-27 |
| Primary Completion | 2027-04-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-04-27 with a primary completion date of 2027-04-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness. To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma. The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).
Eligibility Criteria
Inclusion Criteria: * Men and women aged 18 and over * Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital * mean visual field deficit (MD) \>10dB Exclusion Criteria: * Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) * PPR (retinal PanPhotocoagulation), retinal cerclage * Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) * AMD and other macular pathologies that can lead to central visual field deficits * Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) * Loss of fixation point preventing visual field formation Pregnant or breast-feeding women * Protected adults under guardianship or curatorship * with unreliable visual fields (false positives and false negatives \> 33%) * with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06274593 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06274593 currently recruiting?
Yes, NCT06274593 is actively recruiting participants. Contact the research team at jeanbatiste.ducloyer@chu-nantes.fr for enrollment information.
Where is the NCT06274593 trial being conducted?
This trial is being conducted at Nantes, France, Nantes, France.
Who is sponsoring the NCT06274593 clinical trial?
NCT06274593 is sponsored by Nantes University Hospital. The trial plans to enroll 50 participants.